• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与用二甲基富马酸治疗多发性硬化症相关的脱发。

Alopecia associated with dimethyl fumarate treatment for multiple sclerosis.

机构信息

General Hospital Zabok, Zabok, Croatia.

Department of Neurology, Referral Center for Autonomic Nervous System Disorders, University Hospital Center Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia.

出版信息

Wien Med Wochenschr. 2023 Sep;173(11-12):287-289. doi: 10.1007/s10354-023-01007-7. Epub 2023 Mar 15.

DOI:10.1007/s10354-023-01007-7
PMID:36920580
Abstract

After 2 weeks of treatment, a woman with multiple sclerosis treated with dimethyl fumarate developed alopecia. Considering the adverse events, the therapy was discontinued, leading to alopecia regression during the next 3 months. Although the precise mechanism has not been completely elucidated, glutathione depletion or downregulation of aerobic glycolysis are considered to be potential reasons for hair loss induction. The incidence and mechanism of this uncommon adverse reaction to dimethyl fumarate should be further investigated.

摘要

在接受二甲基富马酸酯治疗 2 周后,1 名多发性硬化症女性患者出现脱发。考虑到不良事件,停止了治疗,导致接下来 3 个月内脱发逐渐恢复。尽管确切的机制尚未完全阐明,但谷胱甘肽耗竭或有氧糖酵解下调被认为是导致脱发的潜在原因。应该进一步研究二甲基富马酸酯这种罕见不良反应的发生率和机制。

相似文献

1
Alopecia associated with dimethyl fumarate treatment for multiple sclerosis.与用二甲基富马酸治疗多发性硬化症相关的脱发。
Wien Med Wochenschr. 2023 Sep;173(11-12):287-289. doi: 10.1007/s10354-023-01007-7. Epub 2023 Mar 15.
2
Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis.二甲基富马酸酯治疗多发性硬化症期间的短暂性脱发。
Mult Scler Relat Disord. 2016 May;7:68-9. doi: 10.1016/j.msard.2016.03.006. Epub 2016 Mar 17.
3
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.利妥昔单抗与二甲基富马酸在瑞典复发缓解型多发性硬化或临床孤立综合征患者中的安全性和疗效:一项盲法、3 期、随机对照试验。
Lancet Neurol. 2022 Aug;21(8):693-703. doi: 10.1016/S1474-4422(22)00209-5.
4
Allergy and dimethyl fumarate treatment in a patient with multiple sclerosis.一名多发性硬化症患者的过敏反应与富马酸二甲酯治疗
J Neurol Sci. 2020 Nov 15;418:117104. doi: 10.1016/j.jns.2020.117104. Epub 2020 Aug 22.
5
Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS).延迟释放富马酸二甲酯在小儿复发型多发性硬化症(FOCUS)患者中的安全性和疗效。
Pediatr Neurol. 2018 Jun;83:19-24. doi: 10.1016/j.pediatrneurol.2018.03.007. Epub 2018 Mar 22.
6
Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate.从全血细胞计数中简单的参数可以预测接受二甲基富马酸酯治疗的 MS 患者的淋巴细胞减少、不良反应和疗效。
Mult Scler Relat Disord. 2023 Jun;74:104699. doi: 10.1016/j.msard.2023.104699. Epub 2023 Apr 3.
7
Medication persistence among people with multiple sclerosis in Slovenia treated with dimethyl fumarate.在斯洛文尼亚接受二甲基富马酸酯治疗的多发性硬化症患者中的药物持久性。
Curr Med Res Opin. 2023 Nov;39(11):1489-1496. doi: 10.1080/03007995.2023.2265299. Epub 2023 Oct 9.
8
Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis.富马酸二甲酯作为复发缓解型多发性硬化症治疗药物的安全性和持久性
Farm Hosp. 2020 Dec 30;45(2):73-76. doi: 10.7399/fh.11567.
9
Whole blood miRNAs in relapsing MS patients treated with dimethyl fumarate in the phase 4 TREMEND trial.在 4 期 TREMEND 试验中,用二甲基富马酸治疗复发性多发性硬化症患者的全血 microRNAs。
J Neuroimmunol. 2023 Aug 15;381:578145. doi: 10.1016/j.jneuroim.2023.578145. Epub 2023 Jun 26.
10
Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate.用富马酸二甲酯治疗的多发性硬化症患者的药物依从性和健康结局
Mult Scler Relat Disord. 2023 Apr;72:104615. doi: 10.1016/j.msard.2023.104615. Epub 2023 Mar 15.

引用本文的文献

1
Autoimmune neurology-a rapidly evolving field.自身免疫性神经病学——一个快速发展的领域。
Wien Med Wochenschr. 2024 Feb;174(1-2):1-3. doi: 10.1007/s10354-023-01023-7. Epub 2023 Nov 3.

本文引用的文献

1
Compartmentalised metabolic programmes in human anagen hair follicles: New targets to modulate epithelial stem cell behaviour, keratinocyte proliferation and hair follicle immune status?人类生长期毛囊中的区室化代谢程序:调节上皮干细胞行为、角质形成细胞增殖和毛囊免疫状态的新靶点?
Exp Dermatol. 2021 May;30(5):645-651. doi: 10.1111/exd.14300. Epub 2021 Mar 1.
2
The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study.选择性口服免疫调节剂 Vidofludimus 治疗活动期类风湿关节炎患者:COMPONENT 研究的安全性结果。
Drugs R D. 2019 Dec;19(4):351-366. doi: 10.1007/s40268-019-00286-z.
3
Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity.
富马酸二甲酯通过靶向 GAPDH 和有氧糖酵解来调节免疫。
Science. 2018 Apr 27;360(6387):449-453. doi: 10.1126/science.aan4665. Epub 2018 Mar 29.
4
Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis.二甲基富马酸酯治疗多发性硬化症期间的短暂性脱发。
Mult Scler Relat Disord. 2016 May;7:68-9. doi: 10.1016/j.msard.2016.03.006. Epub 2016 Mar 17.
5
Teriflunomide in Patients with Relapsing-Remitting Forms of Multiple Sclerosis.来氟米特用于复发缓解型多发性硬化症患者。
CNS Drugs. 2016 Jan;30(1):41-51. doi: 10.1007/s40263-015-0299-y.
6
Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis.用于治疗多发性硬化症的新型口服药物的分子药效学
Drug Des Devel Ther. 2014 May 19;8:555-68. doi: 10.2147/DDDT.S52428. eCollection 2014.
7
[A case of acute intermittent porphyria with abdominal and neurologic manifestations and with reversible generalized alopecia].
Arch Patol Clin Med. 1965 Oct;42(1):45-52.